SpeeDx Expand SARS-CoV-2 Variant Analysis Pipeline

Additional research reagents to detect mutations associated with delta variant of concern now available

News provided by

Aug. 18, 2021 11:00

A

Size

A A A A

SYDNEY--(Business Wire / Korea Newswire)--SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have expanded their product line of research reagents for COVID-19 variant analysis to include a mutation connected to the SARS-CoV-2 Delta variant of concern (VOC). The recently launched PlexPrime® SARS-CoV-2 Genotyping[*] product line utilises the company’s unique universal substrate approach and patented multiplexing technology to offer a streamlined solution to labs seeking to identify key VOCs in their positive SARS-CoV-2 sample population.

“We’re seeing labs around the globe struggling to keep up with requests for sequencing positive specimens as they contribute to the monitoring of VOCs,” said Colin Denver, SpeeDx CEO. “Incorporating a PCR-based variant identification approach compatible with their COVID-19 frontline testing workflow is a straightforward solution to remove laboratory bottlenecks and focus attention on the samples that are truly required for further investigation.”

PlexPrime® SARS-CoV-2 P681R Delta* is a single well mix designed to detect the P681R spike mutation of SARS-CoV-2 found in B.1.617.2 (Delta) VOC[1], in addition to an RdRp gene target of SARS-CoV-2. This reagent is the second product in the PlexPrime® SARS-CoV-2 Genotyping portfolio and can be used as a stand-alone reflex or combined with PlexPrime® SARS-CoV-2 Alpha/Beta/Gamma+. Compatible with standard qPCR instrumentation, the tests can be used with liquid handling automation and reduce the manual process of preparing positive samples for sequence analysis by focusing downstream activities only on key samples of interest.

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com

[*]available as Research Use Only reagents not for use in diagnostic procedures

References

[1] SARS-CoV-2 Variant Classifications and Definitions. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. Found at: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html

View source version on businesswire.com: https://www.businesswire.com/news/home/20210816005769/en/

Website: https://plexpcr.com/

View Korean version of this release

Contact

SpeeDx
Madeline O’Donoghue
Global Marketing Director
+61 406 582 808
madelineo@speedx.com.au

This news is a press release provided by SpeeDx Pty. Ltd.. Korea Newswire follows these editorial guidelines.

SpeeDx Pty. Ltd. News Releases

SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio

SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have further expanded their product line of research reagents for COVID-19 variant analysis to include a key characteristic mutation connected to the SARS-CoV-2 Lambda variant of interest (VOI). The PlexPrime® S...

2021년 10월 7일 14:10

스피덱스, 제2형 중증급성호흡기증후군 코로나19 유전형 시약 포트폴리오의 적용 범위 확대

혁신적인 분자 진단 솔루션 개발 업체 스피덱스(SpeeDx Pty. Ltd)가 코로나19 변이 분석용 연구 시약 제품군을 추가로 확대해 SARS-CoV-2(제2형 중증급성호흡기증후군)의 관심 변이(variant of interest, VOI)인 SARS-CoV-2 람다 변이와 관련한 주요 특성의 변이를 포함하게 됐다. 스피덱스의 PlexPrime® SARS...

2021년 10월 7일 14:10

... More

More News

All News Releases